🔍

JUBLPHARMA - Jubilant Pharmo

📊 NSE: JUBLPHARMA 🏢 Pharmaceuticals - Indian - Bulk Drugs 📅 Last Updated: 12/14/2025 8:43

📢 Recent Corporate Announcements

Jubilant Pharmova to Host FY 2026 Earnings Webinar on May 22, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Apr 2026, 09:01 PM

Jubilant Pharmova has scheduled its earnings webinar for the full financial year 2025-26 on May 22, 2026, at 6:00 PM IST. The management will discuss the company's financial performance across its diverse segments, including Radiopharma, CDMO, and CRDMO. The session will include a formal commentary followed by an interactive Q&A for registered participants. This event is critical for understanding the growth trajectory of its US radiopharmacy network, which currently consists of 45 locations.

Earnings webinar for FY 2026 scheduled for May 22, 2026, at 18:00 IST.
Company operates a significant US network of 45 radiopharmacies.
Global workforce consists of approximately 5,500 multicultural employees.
Webinar will cover performance in Radiopharma, Allergy Immunotherapy, CDMO, and CRDMO segments.
Mandatory pre-registration is required for the Zoom-based interactive session.

💡 Investors should register for the webinar to gain insights into the company's FY26 performance and management's outlook for the US Radiopharma and CDMO markets. Monitor the stock exchange filings for the presentation slides which will be released prior to the call.

Jubilant Pharmova Promoters File Annual Non-Encumbrance Disclosure

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Apr 2026, 06:11 PM

The Hari Shanker Bharti Family Trust, representing the promoter group of Jubilant Pharmova, has submitted its annual disclosure under Regulation 31(4) of the SEBI (SAST) Regulations. This filing confirms that the promoters, along with persons acting in concert, have not created any new encumbrances or pledges on their shareholding during the financial year. This is a mandatory annual compliance requirement intended to ensure transparency regarding the status of promoter-held shares. The disclosure provides assurance that no hidden liens have been placed on the promoter's equity stake.

Annual declaration submitted under Regulation 31(4) of SEBI Substantial Acquisition of Shares and Takeovers Regulations.
Filed by Hari Shanker Bharti Family Trust on behalf of the promoter group.
Confirms that no undisclosed encumbrances were made on promoter shares during the fiscal year.
Maintains regulatory transparency regarding the stability of promoter shareholding.

💡 No action is required as this is a routine regulatory filing confirming the status quo. Investors should view this as a standard transparency measure.

Jubilant Pharmova Submits SEBI Compliance Certificate for Q4 FY2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Apr 2026, 06:04 PM

Jubilant Pharmova Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Alankit Assignments Limited, covers the quarter ended March 31, 2026. It confirms that physical share certificates received for dematerialization have been processed, mutilated, and cancelled. This filing is a standard administrative procedure to ensure the accuracy of the company's electronic shareholding records.

Compliance certificate submitted for the quarter ended March 31, 2026
Issued by Registrar and Share Transfer Agent, M/s Alankit Assignments Limited
Confirms that physical share certificates were dematerialized and the depository substituted as the registered owner
Verification that securities comprised in the certificates are listed on the Stock Exchanges

💡 No action is required from investors as this is a routine regulatory filing. Monitor the company for upcoming financial results for the full fiscal year.

Jubilant Pharmova Notifies Shareholders on Transfer of Unclaimed Shares and Dividends to IEPF

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Mar 2026, 08:02 PM

Jubilant Pharmova has issued a formal notice to shareholders regarding the mandatory transfer of equity shares and unpaid dividends to the Investor Education and Protection Fund (IEPF). This regulatory action applies to dividends that have remained unclaimed for seven consecutive years, specifically starting from the 2018-19 financial year. Shareholders must submit their claims to the company's registrar, Alankit Assignments Limited, by May 15, 2026, to prevent the transfer. The final transfer of these assets to the IEPF Authority is scheduled for October 31, 2026.

Transfer applies to dividends and shares unclaimed for 7 consecutive years starting from FY 2018-19.
Deadline for shareholders to claim from the company is May 15, 2026.
Unclaimed dividends for FY 2018-19 are due for transfer to IEPF on October 31, 2026.
Notice covers historical shares from predecessor entities including Ramganga Fertilizers and Vam Organic Chemicals.
Post-transfer, shareholders must file Form IEPF-5 with the IEPF Authority to recover assets.

💡 Long-term shareholders should verify their dividend records from 2018-19 onwards and contact the registrar if any payments are missing. If shares are transferred to IEPF, investors will need to follow a more rigorous government claim process to reclaim their holdings.

Jubilant Pharmova Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Mar 2026, 03:48 PM

Jubilant Pharmova Limited has announced the closure of its trading window for all designated persons starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming financial results. The window will remain closed until 48 hours after the announcement of the audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. This is a standard regulatory procedure for listed companies to prevent insider trading before price-sensitive information is made public.

Trading window closure begins on Wednesday, April 1, 2026
Closure is related to the audited financial results for the quarter and year ending March 31, 2026
Window will reopen 48 hours after the results are officially declared to the stock exchanges
The specific date for the Board Meeting to declare results will be announced in due course

💡 No action is required as this is a routine regulatory filing. Investors should wait for the announcement of the board meeting date to track the company's financial performance.

Jubilant Pharmova's Montreal Facility Receives USFDA OAI Classification

🔴 NEGATIVE ⭐ 7/10

REGULATORY 📅 13 Feb 2026, 11:10 PM

Jubilant Pharmova's contract manufacturing facility in Montreal, Canada (CMO Montreal), has received an 'Official Action Indicated' (OAI) classification from the USFDA following an audit conducted in October and November 2025. An OAI status typically implies that the regulator may withhold approvals for new products from the site until issues are resolved. However, the company has already implemented remediation measures and resumed production operations at the facility in Q4'FY26. The company continues to work closely with the USFDA to address the specific audit observations.

USFDA classifies CMO Montreal facility as Official Action Indicated (OAI) following late 2025 audit
Production operations at the site have successfully resumed in Q4'FY26 after remediation efforts
The facility is a strategic alliance under Jubilant HollisterStier, focusing on sterile injectables and ophthalmics
Jubilant Pharmova is working with the USFDA to resolve all outstanding regulatory observations

💡 Investors should monitor the timeline for the USFDA to upgrade the facility's status from OAI, as this classification can delay new product launches. While the resumption of production is a positive operational step, the regulatory risk remains until a successful re-inspection or close-out letter is received.

Jubilant Pharmova Q3 Revenue Rises 17% to Rs 2,123 Cr; CDMO Growth Offsets Montreal Shutdown

🔵 WATCH ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 12:48 PM

Jubilant Pharmova reported a solid 17% YoY revenue growth in Q3 FY26, reaching Rs 2,123 crore, driven by a 49% surge in the CDMO Sterile Injectables segment. However, normalized PAT declined by 17% to Rs 86 crore, and EBITDA margins contracted to 14.5% due to a temporary remediation-related shutdown at the Montreal facility. The company's leverage improved with Net Debt/EBITDA falling to 1.3x from 1.5x in the previous quarter. Management expects margin recovery in Q4 as production has resumed at the Montreal site and new capacities ramp up.

Revenue grew 17% YoY to Rs 2,123 Cr, while 9M FY26 revenue reached Rs 5,990 Cr (up 13%).
CDMO Sterile Injectables revenue jumped 49% YoY to Rs 457 Cr, supported by the new Line 3 in Spokane.
EBITDA margins contracted by 172 bps YoY to 14.5% due to Montreal facility shutdown and remediation costs.
Ruby-Fill installation base grew by 37% in 9M FY26, significantly outpacing the 21% growth in FY25.
Generics business remained profitable for the third consecutive quarter with 13% revenue growth.

💡 Investors should focus on the margin recovery trajectory in Q4 as the Montreal facility resumes operations and high-margin Radiopharma products scale. The strong top-line growth in CDMO and Radiopharma provides a positive long-term outlook despite temporary operational headwinds.

Jubilant Pharmova Q3 Standalone Net Profit Rises 24.5% YoY to ₹66 Million

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 12:40 PM

Jubilant Pharmova reported a 20% YoY growth in standalone revenue to ₹673 million for the quarter ended December 31, 2025. Profit before tax from continuing operations saw a significant surge of 90% YoY, reaching ₹101 million, primarily driven by a sharp reduction in finance costs. The company successfully completed the slump sale of its API business to its subsidiary, Jubilant Biosys, on September 1, 2025, which is now reflected as discontinued operations. Total net profit for the quarter stood at ₹66 million, up from ₹53 million in the corresponding quarter of the previous year.

Standalone revenue from operations increased 20% YoY to ₹673 million in Q3 FY26.
Profit before tax from continuing operations surged 90% YoY to ₹101 million.
Finance costs significantly decreased to ₹9 million from ₹33 million in the year-ago period.
The API business transfer was completed for a net asset value of ₹5,956 million on September 1, 2025.
Total comprehensive income for the period stood at ₹67 million versus ₹51 million YoY.

💡 Investors should view the sharp reduction in finance costs and the restructuring of the API business as positive steps toward operational efficiency. Monitor the consolidated results for a clearer picture of the group's overall growth trajectory post-restructuring.

Jubilant Pharmova to Meet 29 Institutional Investors at Nuvama Conference on Feb 9

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 02 Feb 2026, 09:46 PM

Jubilant Pharmova has scheduled physical meetings with 29 major institutional investors on February 9, 2026, in Mumbai. The list includes high-profile entities such as Abu Dhabi Investment Authority, Goldman Sachs Asset Management, and HDFC Life Insurance. These meetings, organized by Nuvama Institutional Equities, will focus on the company's Q3 FY26 earnings. The financial results for the quarter are slated for disclosure on February 6, 2026, just prior to these meetings.

Scheduled meetings with 29 institutional investors including ADIA, Fidelity, and Goldman Sachs
Meetings to be held on February 9, 2026, as part of the Nuvama India Conference 2026
Discussions will center on Q3 FY26 earnings presentation following the Feb 6 results release
Broad participation from domestic funds like ICICI Prudential, HDFC Life, and Invesco Mutual Fund

💡 Investors should focus on the Q3 FY26 financial results to be released on February 6, as these will form the basis of institutional discussions. The high level of institutional interest suggests a need to watch for potential post-result volatility.

Jubilant Pharmova to Meet 29 Institutional Investors at Nuvama Conference on Feb 9, 2026

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 02 Feb 2026, 09:43 PM

Jubilant Pharmova has scheduled physical meetings with 29 major institutional investors on February 9, 2026, in Mumbai. The meetings, organized by Nuvama Institutional Equities, include marquee names such as Abu Dhabi Investment Authority, Goldman Sachs, and HDFC Life. Management will discuss the Q3 FY26 earnings, which are scheduled to be released on February 6, 2026. This high level of institutional engagement indicates significant market interest in the company's upcoming financial results and strategic outlook.

Management to meet 29 institutional investors physically in Mumbai on February 9, 2026.
Key participants include Abu Dhabi Investment Authority, Goldman Sachs Asset Management, and ICICI Prudential AMC.
Meetings are part of the Nuvama India Conference 2026.
Discussions will focus on Q3 FY26 earnings presentation following the official disclosure on February 6, 2026.

💡 Investors should focus on the Q3 FY26 financial results to be released on February 6, as these will form the basis of the institutional discussions. The strong interest from global and domestic funds is a positive sentiment indicator but does not change immediate fundamentals.

Jubilant Pharmova Submits SEBI Compliance Certificate for Q3 FY2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 07:09 PM

Jubilant Pharmova Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Alankit Assignments Limited, confirms the processing of dematerialization requests for the quarter ended December 31, 2025. It verifies that physical share certificates received were duly cancelled and the depository's name was updated in the records. This filing is a standard administrative requirement to ensure the integrity of the company's shareholding data.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Share Transfer Agent, M/s Alankit Assignments Limited
Confirms that dematerialized securities are listed on the BSE and NSE
Confirms physical certificates were mutilated and cancelled after verification
Ensures adherence to SEBI (Depositories and Participants) Regulations, 2018

💡 No action is required from investors as this is a routine regulatory filing. Focus should remain on the company's operational performance and upcoming financial results.

Jubilant Pharmova Reports Nil Requests in Special Window for Physical Share Transfers

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Jan 2026, 06:18 PM

Jubilant Pharmova has submitted a regulatory update regarding the special window for re-lodgement of physical share transfer requests as of December 31, 2025. This filing is in compliance with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97. The company's Registrar and Share Transfer Agent, Alankit Assignments Limited, reported that zero requests were received or processed during the month. This is a standard administrative disclosure with no impact on the company's financial performance.

Zero (Nil) requests received for re-lodgement of physical share transfers during the month ending December 31, 2025.
Zero (Nil) requests were processed, approved, or rejected by the Registrar, Alankit Assignments Limited.
Compliance filing follows the SEBI Circular dated July 2, 2025, regarding physical share transfer mechanisms.
The report confirms the status of the special window as of the end of the 2025 calendar year.

💡 No action is required for the majority of investors. Shareholders still holding physical certificates are encouraged to dematerialize their holdings for easier liquidity and compliance.

Jubilant Pharmova Receives Rs 22.10 Crore Income Tax Demand for FY 2020

🔵 WATCH ⭐ 4/10

LEGAL 📅 31 Dec 2025, 12:56 PM

Jubilant Pharmova Limited has received a tax demand order of Rs 22.10 crore from the Income Tax Department for the financial year 2020. The demand is primarily attributed to arithmetical errors, transfer pricing adjustments, and disallowance of certain expenses. The company believes the order contains mistakes apparent from the records and has ignored their previous contentions. Management plans to file a rectification application or appeal, expecting the demand to be deleted without material financial impact.

Tax demand of Rs 22.10 crore raised by the Income Tax Department, Moradabad for FY 2020.
Issues cited include arithmetical errors, transfer pricing adjustments, and expense disallowances.
Company intends to file a rectification application and/or an appeal before the ITAT.
Management expects the demand to be vacated and does not anticipate material financial implications.
The order was received by the company on December 30, 2025.

💡 Investors should monitor the outcome of the rectification or appeal process. Given the company's stance on arithmetical errors, this is likely a routine tax dispute with limited immediate risk to the stock.

Jubilant Pharmova acquires 100% stake in Canadian entity for CAD 30,000

🟡 NEUTRAL ⭐ 4/10

M&A 📅 30 Dec 2025, 05:49 PM

Jubilant Pharmova's subsidiary, Jubilant Generics Limited, has acquired a 100% stake in Jubilant Pharmaceuticals Inc., Canada, for a cash consideration of CAD 30,000 (approximately INR 0.20 crores). The target entity is a newly incorporated company (June 2025) that has not yet commenced business operations and currently reports nil turnover. This acquisition is a strategic move to establish a branded generic business and strengthen the company's presence in the Canadian market. While the financial outlay is minimal, it sets the foundation for future revenue growth in North America.

Acquisition of 100% shareholding (30,000 shares) in Jubilant Pharmaceuticals Inc., Canada.
Total investment cost is CAD 30,000, which is approximately INR 0.20 crores.
Target entity was incorporated on June 17, 2025, and has zero turnover to date.
Strategic objective is to establish a branded generic business and expand Canadian market presence.

💡 The investment is negligible relative to the company's size, so no immediate action is required. Investors should treat this as a routine structural setup for future international expansion.

Jubilant Pharmova to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Dec 2025, 03:49 PM

Jubilant Pharmova Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is a standard procedure ahead of the declaration of the company's unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons until 48 hours after the results are officially announced to the stock exchanges. The specific date for the board meeting to approve these results will be communicated in due course.

Trading window closure effective from Thursday, January 1, 2026.
Closure pertains to the financial results for the quarter and nine months ending December 31, 2025.
Window will reopen 48 hours after the financial results are disclosed to BSE and NSE.
Designated persons and insiders are prohibited from trading in company securities during this period.

💡 This is a routine regulatory filing with no immediate impact on stock fundamentals; investors should monitor for the upcoming board meeting date to assess Q3 performance.

View All JUBLPHARMA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue for Q2'FY26 grew 12% YoY to INR 1,966 Cr, driven by the new third line in CDMO Sterile Injectables and growth in Radiopharma, Allergy Immunotherapy, and CRDMO. In FY25, CDMO Sterile Injectables EBITDA grew 52% with margins expanding from 17.2% to 23.0%, while CRDMO EBITDA rose 32.3% with margins improving from 15.5% to 19.4%.

Geographic Revenue Split

The US market is the primary revenue driver, contributing 82% of total revenue in H1'FY26. The origin of goods sold in the US is 72% from the US, 17% from Canada, and 12% from India.

Profitability Margins

Normalised PAT Margin for Q2'FY26 stood at 6.3%, an improvement of 50 bps YoY. For H1'FY26, the Normalised PAT margin was 5.8%, up 96 bps YoY. FY25 Consolidated Net Profit surged to INR 836.3 Cr from INR 72.7 Cr in FY24, reflecting a substantial turnaround in the Generics segment and operational excellence.

EBITDA Margin

EBITDA margin for Q2'FY26 was 17.8%, reflecting a 24 bps YoY increase. H1'FY26 EBITDA margin was 16.8%, up 40 bps YoY. Consolidated EBITDA for FY25 was INR 1,230.5 Cr, a 26.9% increase over FY24.

Capital Expenditure

The company is executing a CAD 145 million (approx. INR 900 Cr) modernization and capacity expansion project in Montreal to double sterile production capacity. Additionally, revenue generation has commenced from the new third line at the Spokane, US facility in Q2'FY26.

Credit Rating & Borrowing

The company has outstanding Secured Redeemable Unlisted Non-Convertible Debentures (NCDs) of INR 70 Cr as of March 31, 2025, with the tenure extended by five years. Finance costs were reduced in H1'FY26, contributing to a 32% YoY increase in Normalised PAT to INR 227 Cr.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (API), sterile fill-finish components, and chemicals for radiopharmaceuticals. The API business reported revenue of INR 137 Cr in Q2'FY26, up 8% YoY.

Import Sources

Sourcing is diversified across the US (72% of US sales origin), Canada (17%), and India (12%), with a 'China plus one' strategy implemented to increase backward integration and supplier resilience.

Key Suppliers

Not specifically named in the documents, but the company utilizes select Contract Manufacturing Organisations (CMOs) for its Generics business and maintains a diversified supplier base for its API segment.

Capacity Expansion

CDMO Sterile Injectables: New third line at Spokane, US is now operational. Montreal, Canada: CAD 145 million project to double sterile production capacity is expected to be operational in H2 FY26.

Raw Material Costs

Total operating expenditure for FY25 was INR 6,060.8 Cr on a consolidated basis, representing approximately 83.7% of revenue. The company focuses on cost optimization and improved revenue mix toward high-margin custom manufacturing.

Manufacturing Efficiency

The Generics segment transitioned from in-house manufacturing to a CMO-based model to focus on profitable product lines and margin enhancement. CDMO API asset utilization is being increased by shifting the mix toward custom manufacturing.

Logistics & Distribution

The company maintains a strong sales and marketing presence in the US, leveraging products from its India facility and CMOs to serve major wholesalers and retail chains.

📈 Strategic Growth

Expected Growth Rate

11%

Growth Strategy

Growth will be achieved through the ramp-up of the new third line in Spokane, doubling capacity in Montreal by H2 FY26, and scaling contracts with three new large pharmaceutical companies onboarded in the last year. The company is also exploring monetization of its Proprietary Novel Drugs (JBI-802, JBI-778) through licensing or external fundraising following clinical data readouts in CY 2026.

Products & Services

Radiopharmaceuticals, Allergy Immunotherapy, Sterile Injectables (CDMO), Solid Dosage Formulations (Generics), Drug Discovery Services (CRDMO), and Proprietary Novel Drugs for oncology.

Brand Portfolio

Jubilant Biosys, Jubilant HollisterStier, Jubilant Cadista, Draximage, and Jubilant Therapeutics.

New Products/Services

Proprietary Novel Drugs JBI-802 and JBI-778 are in clinical trials; JBI-2174 has launched a Phase I first-in-human study for cancer sub-sets in India.

Market Expansion

Expansion into new geographies for existing products and increasing partnerships with large pharma companies to leverage expanded infrastructure in India and North America.

Market Share & Ranking

Recognized as a 'Partner of Choice' by leading global pharmaceutical companies; Jubilant HollisterStier is a leading global CMO in sterile fill-finish.

Strategic Alliances

Partnership with the Government of Canada (Strategic Innovation Fund) providing CAD 23.8 million and the Province of Quebec providing CAD 25 million for capacity expansion.

🌍 External Factors

Industry Trends

The industry is shifting toward outsourced sterile manufacturing and specialized drug discovery. Jubilant is positioning itself by doubling sterile capacity and integrating API with drug discovery services.

Competitive Landscape

Competes with global CDMOs and generic manufacturers; competitive advantage is derived from a diversified portfolio and manufacturing presence in North America.

Competitive Moat

Moat is sustained by high regulatory barriers (US FDA/international compliance), specialized manufacturing capabilities in Radiopharma and Allergy, and long-term 'Partner of Choice' relationships with large pharma.

Macro Economic Sensitivity

Sensitive to US healthcare spending and biotech funding environments; softening demand in the biotech sector was noted due to uncertain economic conditions.

Consumer Behavior

Increased end-user awareness of cybersecurity risks and a shift toward specialized oncology treatments are driving demand for the company's novel drug pipeline.

Geopolitical Risks

The proposed US Biosecure Act is expected to drive 'friend-shoring' demand toward Indian CROs, benefiting Jubilant's CRDMO business.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to US FDA current Good Manufacturing Practices (cGMP) and Regulation 24A of SEBI Listing Regulations for material subsidiaries.

Environmental Compliance

The company maintains an Enterprise Risk Management program and ESG training for personnel to comply with changing global standards.

Taxation Policy Impact

Effective tax rate for Q2'FY26 was abnormally higher due to a one-time net tax expense of INR 13 Cr related to the slump sale of the API business.

Legal Contingencies

Jubilant Biosys Limited received an Adjudication Order for GST, interest, and penalty for FY 2021-22; the company is contesting this before the GST Appellate Authority and expects no financial impact.